What is Mimedx Group Inc Annual Revenue?

Mimedx Group Inc Annual Revenue rose 8.52%, in the last year to $348.88 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

What is Mimedx Group Inc Annual Net Profit?

Mimedx Group Inc Annual Net Profit fell 27.15% in the last year to $42.42 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

What is Mimedx Group Inc Price to Earning Ratio?

Mimedx Group Inc Price to Earning Ratio is 22.82, lower than its sector PE ratio of 29.09.

What is Mimedx Group Inc Stock Price?

Mimedx Group Inc Stock Price rose 4.45% and underperformed its sector by 2.23% in the past year.

What is Mimedx Group Inc Quarterly Revenue?

Mimedx Group Inc Quarterly Revenue rose 7% YoY to $92.91 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

What is Mimedx Group Inc Quarterly Net profit?

Mimedx Group Inc Quarterly Net profit fell 86.09% YoY to $7.44 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

What is Mimedx Group Inc Debt to Equity Ratio?

Mimedx Group Inc Debt to Equity Ratio of 0.1 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Mimedx Group Inc Return on Equity(ROE)?

Mimedx Group Inc Return on Equity(ROE) for the last financial year was 25.26%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

What is Mimedx Group Inc Mutual Fund Holding?

Mimedx Group Inc Mutual Fund Holding increased by 0.08% in the last quarter to 27.97.

What is Mimedx Group Inc Promoter Share Holding?

Mimedx Group Inc Promoter Share Holding increased by 0.26% in the most recent quarter to 7.21%.

What is Mimedx Group Inc Interest Coverage Ratio?

Mimedx Group Inc Interest Coverage Ratio is 57.95, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

How is the Mimedx Group Inc today?

The Mimedx Group Inc today is trading in the down by -1.65% at 6.57.

How has Mimedx Group Inc performed historically?

The Mimedx Group Inc is currently trading down -1.65% on an intraday basis in the past week the index fell -3.95%. The index has been down -27.96% in the past quarter and rose 4.45% in the past year. You can view this in the overview section.

Mimedx Group Inc XNAS: MDXG

Mimedx Group Inc Live Share Price Today, Share Analysis and Chart

Name: Mimedx Group Inc: Is Infosys Ltd. worth buying?
Item: Mimedx Group Inc
Rating: 2.28575
Author: Trendlyne DVM scores

Mid-range Performer

Download real time

6.57 -0.11 (-1.65%)

35.21% Fall from 52W High

13,886 XNAS Volume

XNAS 21 Apr, 2025 9:52 AM (EDT)

Board Meeting

The next board meeting for Mimedx Group Inc is on 30 Apr 2025 for the purpose of MiMedx Group Inc First Quarter Earnings Conference Call for 2025 See details

Mimedx Group Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	968.2
PE TTM High in industry Unavailable in chosen country	22.8
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.8
Price to Book Below industry Median Unavailable in chosen country	5
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	69.8
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	7
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	8.5
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-86.1
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-27.2
Operating Profit Margin Qtr % Below industry Median Unavailable in chosen country	12
Operating Profit Margin TTM % High in industry Unavailable in chosen country	17
Piotroski Score High in industry Unavailable in chosen country	6
Rel Perf vs Sector quarter% Unavailable in chosen country	-20.1
ROE Annual % High in industry Unavailable in chosen country	25.3
RoA Annual % High in industry Unavailable in chosen country	16.9

All financials are in USD Million and price data in USD

Medium Financial Strength

50.0 / 100

Mid Valuation

41.5 / 100

Technically Neutral

41.4 / 100

Mid-range Performer These stocks average quality, financial and technical aspects make them being considered by the investor who are not looking for high risk stocks. View Similar Embed DVM

1Yr Price target upside is 98%

5 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Buy Zone

34.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Mimedx Group Inc Stock Price Analysis

Day Price Range -1.6% 1 Day return Unavailable in chosen country	6.6 (LTP) 6.56.6 LowHigh
Week Price Range -4.0% 1 Week return Unavailable in chosen country	6.6 (LTP) 6.57 LowHigh
Month Price Range -17.6% 1 Month return Unavailable in chosen country	6.6 (LTP) 6.58.1 LowHigh
52 Week Price Range 4.4% 1 Year return Unavailable in chosen country	6.6 (LTP) 5.510.1 LowHigh

View full Share Price History

Mimedx Group Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Mimedx Group Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

0.3

Avg. Estimate

0.3

Low Estimate

0.3

High Estimate

0.3

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 3.6% in FY25

Consensus Recommendation

5 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 5 analysts for Mimedx Group Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Mimedx Group Inc Stock Analysis

Mimedx Group Inc stock analysis with key metrics, changes, and trends.

Mimedx Group Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$348.88 M	8.52%	positive	Annual Revenue rose 8.52%, in the last year to $348.88 M. Its sector's average revenue growth for the last fiscal year was 8.57%.
Annual Net Profit	$42.42 M	27.15%	negative	Annual Net Profit fell 27.15% in the last year to $42.42 M. Its sector's average net profit growth for the last fiscal year was 4.36%.
Price to Earning Ratio	22.82	-	positive	Price to Earning Ratio is 22.82, lower than its sector PE ratio of 29.09.
Stock Price	$6.57	4.45%	negative	Stock Price rose 4.45% and underperformed its sector by 2.23% in the past year.
Quarterly Revenue	$92.91 M	7%	positive	Quarterly Revenue rose 7% YoY to $92.91 M. Its sector's average revenue growth YoY for the quarter was 8.5%.
Quarterly Net profit	$7.44 M	86.09%	negative	Quarterly Net profit fell 86.09% YoY to $7.44 M. Its sector's average net profit growth YoY for the quarter was 32.89%.
Debt to Equity Ratio	0.1	-	positive	Debt to Equity Ratio of 0.1 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	25.26 %	25.26%	positive	Return on Equity(ROE) for the last financial year was 25.26%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
Mutual Fund Holding	27.97 %	0.08%	positive	Mutual Fund Holding increased by 0.08% in the last quarter to 27.97.
Promoter Share Holding	7.21 %	0.26%	positive	Promoter Share Holding increased by 0.26% in the most recent quarter to 7.21%.
Interest Coverage Ratio	57.95	-	positive	Interest Coverage Ratio is 57.95, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

VIEW LESS

Loading data..

Mimedx Group Inc - Company Profile

What does Mimedx Group Inc do?

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Mimedx Group Inc Management structure

All Gross Remunerations are in USD

Mr. Joseph H. Capper

Director and Chief Executive Officer

2024

Gross Remuneration

Year

Mr. Douglas C. Rice

Chief Financial Officer and Chief Accounting Officer

2024

Gross Remuneration

2024

Gross Remuneration

Year

Mimedx Group Inc Live Share Price Today, Share Analysis and Chart

35.21% Fall from 52W High

Mimedx Group Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Mimedx Group Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Mimedx Group Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Mimedx Group Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to reduce by 3.6% in FY25

Consensus Recommendation

The consensus recommendation from 5 analysts for Mimedx Group Inc is STRONG BUY

Mimedx Group Inc Stock Analysis

Mimedx Group Inc stock analysis with key metrics, changes, and trends.

Annual Revenue rose 8.52%, in the last year to $348.88 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

Annual Net Profit fell 27.15% in the last year to $42.42 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

Price to Earning Ratio is 22.82, lower than its sector PE ratio of 29.09.

Stock Price rose 4.45% and underperformed its sector by 2.23% in the past year.

Quarterly Revenue rose 7% YoY to $92.91 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

Quarterly Net profit fell 86.09% YoY to $7.44 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

Debt to Equity Ratio of 0.1 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was 25.26%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.08% in the last quarter to 27.97.

Promoter Share Holding increased by 0.26% in the most recent quarter to 7.21%.

Interest Coverage Ratio is 57.95, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Mimedx Group Inc - Company Profile

What does Mimedx Group Inc do?

Mimedx Group Inc Management structure

Mr. Joseph H. Capper

Director and Chief Executive Officer

Mr. Douglas C. Rice

Chief Financial Officer and Chief Accounting Officer

Mimedx Group Inc Board of directors

Ms. Dorothy E. Puhy

Independent Director

Ms. Tiffany P. Olson, M.B.A.

Independent Director

Dr. Phyllis I. Gardner,M.D.

Independent Director

Dr. Michael J. Giuliani, M.D.

Independent Director

Dr. Cato T. Laurencin,M.D.,PhD

Independent Director